TITLE:
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

CONDITION:
Breast Cancer

INTERVENTION:
Denosumab

SUMMARY:

      This study is to evaluate various doses and schedules for denosumab administration and
      characterize the safety profile in this indication.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria: - Histologically or cytologically confirmed breast adenocarcinoma

          -  At least one bone metastasis
      
